Ipamorelin interacts differently with hormone pathways than some other peptides
Current FDA labels document these patterns in detail: Wegovy (semaglutide) lists nausea (44% vs 16% placebo), vomiting (25% vs 6%), diarrhea (30% vs 16%), constipation (24% vs 11%), abdominal distension and eructation, with severe GI events in 4.1% versus 0.9% placebo.[2] Zepbound (tirzepatide) lists nausea, diarrhea, vomiting, constipation, abdominal pain, dyspepsia, eructation, and gastroesophageal reflux disease among common adverse reactions, with severe GI disease as a Warnings and Precautions item.[3] Both labels include postmarketing reports of ileus, severe constipation including fecal impaction, and acute kidney injury related to dehydration from severe GI symptoms
Frailty from sarcopenia decreases quality of life and makes you more likely to fall or fracture a bone
(147) found that a one-month IF regimen, initiated 3 days post-TBI, enhanced the proliferation of hippocampal subgranular zone neural stem cells, increased neuropeptide Y (NPY) expression in the hippocampus, and improved cognitive performance in the Morris water maze test